

# “Situation of STEC infections in Argentina”

Isabel Chinen. [ichinen@anlis.gov.ar](mailto:ichinen@anlis.gov.ar)



**14<sup>th</sup> Annual Workshop of the National Reference Laboratories for *E. coli* in the EU**  
**Rome, ISS, 4-5 November 2019**

# HUS in Argentina

## ◎ High Incidence Rate

8-10/100000 children < 5 years old

~ 400 cases /year

## ◎ In children...

First cause of acute renal failure

Second cause of chronic renal failure

Responsible of 9 % renal transplant

## ◎ STEC associated to 70% of HUS cases

O157:H7 / O145:NM predominant

*Shigella dysenteriae* type 1 NOT isolated

# National Reference Laboratory for HUS & Diarrheas associated to STEC and Diarrheagenic *E. coli*

## Pathogens

{ STEC O157 y non-O157  
Diarrheagenic *E. coli*  
(ETEC, EPEC, EIEC,  
EAEC, DAEC)

- Standardized protocols for the diagnosis and subtyping of strains of human, animal and food origin applied to:
  - Epidemiological surveillance
  - Outbreak investigation

- **Mandatory notification - Ministry of Health Resolution No. 346/00. National Health Surveillance System (SNVS)**
- **National Laboratory Network for the surveillance of Diarrheas and pathogens associated to foodborne diseases**
- **HUS Sentinel Units (25 laboratories)**

# National Reference Laboratory for Hemolytic Uremic Syndrome and Diarrheas associated with STEC

## 1. Isolation and characterization of the microorganism

- Typing: virulence factors, biotype, serotype, antimicrobial resistance
- Subtyping: PFGE and genotyping of Stx1 / Stx2 variants

## 2. Detection of free Shiga toxin in stool samples

Cytotoxicity on Vero cells

## 3. Detection of anti-LPS antibodies

- Recombinant glycoproteins based iELISA for detection of a-O157, a-O145, a-O121, a-O103

## 1- ENRICHMENT & CULTURE



SMAC  
Agar

## 2- SCREENING

PCR - Confluent zone and pools

screening  
mPCR-1  
*eae* / *lt* / *sth* / *stp*

mPCR-1 +

Screening  
mPCR-2  
*IpaH* / *aggR*

mPCR-2 +

Screening  
mPCR-STEC  
*stx*<sub>1</sub> / *stx*<sub>2</sub> / *rfb*<sub>O157</sub>

mPCR-STEC +

## 3- CONFIRMATION

PCR - individual colonies

*eae* (+)  
EPEC isolate

*lt* / *st*<sub>h</sub> / *st*<sub>p</sub> (+)  
ETEC isolate

*IpaH* (+)  
EIEC isolate

*aggR* (+)  
EAEC isolate

*stx*<sub>1</sub> / *stx*<sub>2</sub> / *rfb*<sub>O157</sub> (+)  
STEC isolate


If *stx*<sub>2</sub> (+) *eae* (-)  
EAEC-stx isolate

If *stx*<sub>2</sub> (+) *eae* (-) *aggR* (+)  
EAEC-stx isolate


Biochemical identification and Serotyping

## 4- Report to SNVS 2.0-SISA and deliver the isolates to NRL

# Serotypes of STEC strains



# *stx*-genotypes



Clinical Diagnostic	No. Cases Received NRL	STEC O157 / STEC no-O157	Glyco-iElisa O157 / O145 / O121 ONLY = 221	Stx-MF ONLY=143	Total	
HUS	339	79 (24%) 54 O157 25 no-O157	138 (40%) O157 (85/44%) O145 (49/19%) O121 (4/1%)	8 (2%)	225 (66%)	<b>STECA infections</b> <b>66%</b>
BD	133	19 (14%) 13 O157 6 no-O157	6 (4,5%) O157 (4/2.7%) O145 (2/1%)		25 (19%)	
D	135	36 (27%) 21 O157 15 no-O157			36 (27%)	
<b>Total</b>	<b>607</b>	<b>134 ( 22%)</b>	<b>144 (23,7%)</b>	<b>8 (2%)</b>	<b>286 (47%)</b>	

**SUH / DS / D cases - Total STEC diagnosed = 286/607 (47,1%)**


STEC bacteriological confirmed = 134 (22%)

a-LPS STEC O157/O145/O121= 144 (23,7%)

# OUTBREAKS

Outbreak	STEC-positive cases (No.)	Characteristics of the STEC strains		
		Serotype	Genotypic profile	XbaI-PFGE
1	BD / Healthy contact	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.0011
2	HUS / HUS	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.0650
3	BD / BD	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.0650
4	BD / Healthy contact	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.1058
5	BD / NBD / Healthy contact	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.1309
6	HUS / Healthy contact	O157:H7	<i>stx</i> <sub>2a</sub> / <i>stx</i> <sub>2c</sub> / <i>eae</i> / <i>ehxA</i>	AREXHX01.1356
7	HUS / Healthy contact (2)	O145:NM[H28]	<i>stx</i> <sub>2a</sub> / <i>eae</i> / <i>ehxA</i>	ARENMX01.0316
8	BD / Healthy contact (5)	O145:NM[H28] O157:HNT	<i>stx</i> <sub>2a</sub> / <i>eae</i> / <i>ehxA</i> <i>stx</i> (-)	ARENMX01.0319 AREXHX01.1415
9	HUS / Healthy contact	O145:NM[H28]	<i>stx</i> <sub>2a</sub> / <i>eae</i> / <i>ehxA</i>	ARENMX01.0335
10	HUS / Healthy contact	O145:NM[H28]	<i>stx</i> <sub>2a</sub> / <i>eae</i> / <i>ehxA</i>	ARENMX01.0340
11	HUS / Healthy contact (2)	O112:HNT	<i>stx</i> <sub>2c</sub> / <i>ehxA</i>	ARE12X01.0002

# Diarrheagenic *E. coli*



# DEC vs Clinical diagnosis

	HUS (n=339)	BD (n=133)	D (135)	Total
STEC	79	19	36	134 (63%)
EAEC	15	8	30	53 (24%)
EPEC	6	3	6	15 (7%)
EIEC	2	7	2	11 (5%)
ETEC	0	2	0	2 (1%)
Total	102	39	74	215

# O-antibodies

## HUS-DEC+

	HUS (n=339)	Glyco iELISA
STEC	79	42/47
EAEC	15	6/11
EPEC	6	4/5
EIEC	2	1/2
ETEC	0	0
	102	53/65


Cases	Coinfection / strains
NBD	<ul style="list-style-type: none"> <li>• STEC O157:H7</li> <li>• EAEC</li> </ul>
Healthy contact	<ul style="list-style-type: none"> <li>• STEC O157:H7</li> <li>• STEC O112:HNT</li> </ul>
HUS	<ul style="list-style-type: none"> <li>• STEC O157:H7</li> <li>• EAEC</li> </ul>
HUS	<ul style="list-style-type: none"> <li>• STEC O145:NM[H28]</li> <li>• EAEC-<i>stx+</i> O59:H19</li> </ul>
BD	<ul style="list-style-type: none"> <li>• O145:NM[H28]</li> <li>• O157:HNT</li> </ul>
HUS	<ul style="list-style-type: none"> <li>• O145:NM[H28]</li> <li>• O157:H16</li> </ul>
BD	<ul style="list-style-type: none"> <li>• O145:NM[H28]</li> <li>• O157:HNM</li> </ul>

# PROJECTS



- **Global surveillance and monitoring of the foodborne pathogens/WGS implementation in Argentina**

FDA – Genome TRAKR Project


WHO-FDA Pilot Project



- **wg/cgMLST Strategy for the foodborne surveillance-PulseNet Latinamerica and The Caribbean**  
CDC-PAHO



## REGIONAL WORFLOW Diagnosis & outbreak




# WGS for STEC surveillance – Argentina

Genome TraKr – Pilot Project  
WHO/FDA

## SNPs Tree O157:H7

- Outbreaks
- Case/Food

Tree scale: 100




# **“Enteropathogenic *Escherichia coli*: its importance in human diarrheic disease in Argentina, characterization and virulence factors study”**

1- Retrospective analysis of EAEC strains (Period 2002 - 2017)

2- Prospective study of EAEC (Period 2018)

- General aim: characterize and subtype the strains EAEC and EAEC-stx isolated in Argentina, and to determine the frequency of disease associated with this pathogen from the implementation of a diagnostic protocol.
- Specific objectives:
  - To create the EAEC Database (PFGE patterns, characteristics of the strains and epidemiological data of the patient).
  - To implement the Whole Genome Sequencing (WGS) for the surveillance and identification of new tools associated with epidemic strains.
  - To determine characteristics and phylogeny of EAEC - Stx strains by SGC.
  - To determine ability of causing serious disease.
  - To develop and implement a protocol using a specific real-time PCR and based on the results obtained in the retrospective study, to improve the detection and diagnosis of EAEC strains in the surveillance framework.


# Cases associated with EAEC



170 strains/159 cases associated with EAEC

# EAEC-stx

- 13.5% of total → EAEC-stx
- 23 strains /21 cases



# EAEC-stx


23 strains /21 cases

22      O59:H19 *stx2a aggR* S-TMS  
 1      ONT:H4 *stx2a aggR/aaiC*

HUS and bloody diarrhea cases						Characteristics of EAEC/STEC strains analyzed in the study																
ID No.	Age	Sex	Location	Year	Diagnosis	Serotype	AAF type *	Genes frequently associated with STEC ♦						Genes frequently associated with EAEC♦						Antibiotic resistance ■	Vero cells DC50/90 µl §	
								<i>stx</i> genotype	<i>iha</i>	<i>lpf</i> <sub>026</sub>	<i>lpf</i> <sub>0113</sub>	<i>terA</i>	<i>saa</i>	<i>aggR</i>	<i>aatA</i>	<i>aap</i>	<i>pet</i>	<i>astA</i>	<i>aaiC</i>	<i>pic</i>		
363/05	16 m	M	Buenos Aires	2005	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	< 100
777/05	12 m	M	Buenos Aires	2005	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	400
309/06	15 y	M	Córdoba	2005	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TETRA-TMS	400
975/06 #	92 m	F	Entre Ríos	2006	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	800
12/07	47 m	M	Buenos Aires	2006	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	800
855/07	13 y †	F	Buenos Aires City	2007	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	200
505/07	18 y	M	Buenos Aires	2007	BD	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	400
452/12	76 m	M	Santa Fe	2012	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	400
90/15 #	8 y	M	Chubut	2015	HUS	O59:NM[ <i>flf/C</i> <sub>H19</sub> ]	IV	<i>stx</i> <sub>2a</sub>	+	+	+	-	-	+	+	+	-	-	-	-	S-TMS	600

# EAEC + EAEC-stx

Diagnostic  
Gender  
MLST  
Stx  
Serotype



# *Partnership / International Project*

- Wellcome Trust Sanger Institute (WTSI)
- Food and Drug Administration (FDA)
- Center for Diseases Control and Prevention (CDC)
- PulseNet International
- Istituto di Sanitá
- National Public Health Canada (NPHC)
- Pasteur Institute
- Public Health Ontario (PHO)
- Panamerican Health Organization (PAHO)
- World Health Organization (WHO)

# WGS for Public Health in LA

**WGS for Public  
Health**


National &  
International  
Collaboration/  
PROJECTS

**WSG  
Specific  
events/Projects**

- ✓ Visits
- ✓ Training on job
- ✓ Meetings
- ✓ Courses
- ✓ Technical Support
- ✓ Financial Support
- ✓ Informatic /  
Bioinformatic support

# CONCLUSIONES

- In Argentina, it is installed the capacity for the surveillance of STEC O157 / no-O157, DEC and new pathotypes in human samples
- Implementation of new technology (RT-PCR, iELISA, lateral flow, WGS and MALDI-TOF)
- Reinforcing the capacity for the integrated surveillance (Human-Food-Animal). Ministry of health, Food Agency (INAL) and Animal Agency (SENASA)
  - IHR (WHO/PAHO) autoevaluation
  - Manual of Standards for HUS - Update



THANK

YOU



Servicio Fisiopatogenia